#Italy #biopharmaceuticals #Kedrion Biopharma #plasma-derived therapies #Castelvecchio Pascoli

Kedrion Biopharma Unveils New Identity and Growth Achievements

Kedrion Biopharma, renowned for its contributions in the field of biopharmaceuticals through plasma collection and fractionation, recently reported a substantial financial growth of 10% for the year 2024. With its turnover reaching €1.578 billion, this year showcased consistent increases across various metrics. This announcement is accompanied by the introduction of the company’s new brand identity, which aims to represent its core values and mission in treating serious conditions and rare diseases.

Throughout 2024, Kedrion reported an impressive EBITDA rise of 28%, amounting to €232 million, and a 20% increase in adjusted EBITDA, reaching €279 million. Such results have been attributed to effective financial strategies and enhanced operational management, allowing the company to sustain positive cash flow that can fully support further investments.

As a global entity, Kedrion employs around 5,200 individuals and maintains operations in over 100 countries, with its headquarters situated in Castelvecchio Pascoli, Italy. Moreover, its expansive plasma collection network throughout Europe and the United States supports a robust product portfolio of 38 distinct therapies. These statistics underscore Kedrion's status as a significant player in the plasma-derived therapy landscape.

The launch of the new brand identity unifies all of Kedrion's global affiliates under a single persona, encapsulating the company’s mission to expand accessibility to life-altering medications for patients worldwide. The new logo reflects the concept of fostering connections—symbolizing links among donors, patients, scientists, and caregivers, which are integral to the company's essence. This philosophy drives innovation and operational enhancements tailored for broader patient reach.

Kedrion has always prioritized research and development, particularly in addressing unmet medical needs. The company has made remarkable strides with its unique therapies for extraordinarily rare diseases. Continuing its quest for innovation, Kedrion's development pipeline is progressing with emerging therapies and orphan drug applications aimed at creating novel treatments utilizing proteomics and other innovations from plasma waste.

In its commitment to sustainability, Kedrion is implementing practices to mitigate its environmental impact by promoting efficient use of resources. The company is advancing its Net Zero Plan, engaging with the Science Based Targets Initiative (SBTi) to set and meet ambitious emission reduction targets.

Paolo Marcucci, Chairman of the Board, emphasizes that while 2024’s achievements are commendable, the true measure of success lies beyond financial metrics. “Our commitment is towards building profound relationships with our community, including our patients, collaborators, and advocates,” he states.

Ugo Di Francesco, CEO of Kedrion Biopharma, shares the essence of this new chapter: “We are now prepared to present ourselves as one unified company. Each connection we foster—from donors to employees, impacts lives tremendously. This is what we mean by rare connections, a fundamental value guiding our new identity.”

Along with the branding changes, the updated Kedrion website, set to launch imminently, will provide more insights into the evolving identity of the company.

Kedrion Biopharma stands at the forefront of plasma-derived therapies, creating a landscape where science and patient care converge seamlessly. As they continue to expand their operations and commitment to global health, they reinforce that each connection they facilitate profoundly influences the lives they aim to serve.